| Hazard Information | Back Directory | [Uses]
Monalizumab (IPH2201) is a potentially first-in-class immune checkpoint
inhibitor targeting NKG2A receptors expressed on tumor infiltrating
cytotoxic CD8+ T cells and NK cells. | [Mechanism of action]
Monalizumab is a blocking antibody that prevents the inhibition of
CD8+ T cells and NK cell by tumor cells expressing HLA-E. By acting
simultaneously on innate and adaptive immunity, monalizumab may
re-establish a broad anti-tumor response. |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604862 |
| Website: |
www.biolabreagent.com/ |
|